Literature DB >> 1687129

Inhaled formoterol during one year in asthma: a comparison with salbutamol.

P Arvidsson1, S Larsson, C G Löfdahl, B Melander, N Svedmyr, L Wåhlander.   

Abstract

Eighteen patients, who had previously taken part in a 2 wk cross-over comparison between formoterol and salbutamol, now took part in a one year double-blind study comparing salbutamol 200 micrograms b.i.d. with formoterol 12 micrograms b.i.d. Additional doses were taken when needed and were recorded. Ten patients were started on formoterol and eight on salbutamol. After one month, the patients were allowed to shift to the alternative drug. Two patients withdrew from the study. At the end of the study, 13 of 16 patients were on formoterol, thus showing a long-lasting preference for this drug. Forced expiratory volume in one second (FEV1) dose-response curves for inhaled salbutamol were repeatedly recorded during the study, and no tachyphylaxis was found. One patient stopped taking inhaled steroids but continued taking formoterol and theophylline. He deteriorated with a decreased response to salbutamol. After re-introduction of inhaled steroids his condition improved. This case indicates that effective bronchodilator therapy may mask the deterioration of asthma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1687129

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  19 in total

Review 1.  Long- versus short-acting beta 2-agonists. Implications for drug therapy.

Authors:  L P Boulet
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

Review 2.  Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma.

Authors:  Francine M Ducharme; Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

3.  Bronchodilators: wrong for the lung in the long run?

Authors:  C P van Schayck
Journal:  Br J Gen Pract       Date:  1993-10       Impact factor: 5.386

4.  Do bronchodilators adversely affect the prognosis of bronchial hyperresponsiveness?

Authors:  C P van Schayck; C L van Herwaarden
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

Review 5.  The current debate concerning beta-agonists in asthma: a review.

Authors:  K F Chung
Journal:  J R Soc Med       Date:  1993-02       Impact factor: 5.344

Review 6.  Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists?

Authors:  T D Holimon; C C Chafin; T H Self
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Asthma exacerbations during first therapy with long acting beta 2-agonists.

Authors:  C M Gerrits; R M Herings; H G Leufkens; J W Lammers
Journal:  Pharm World Sci       Date:  1999-06

8.  Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism.

Authors:  A Lindén; A Bergendal; A Ullman; B E Skoogh; C G Löfdahl
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

Review 9.  A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease.

Authors:  Milind P Sovani; Christopher I Whale; Anne E Tattersfield
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma.

Authors:  A Wallin; T Sandström; L Rosenhall; B Melander
Journal:  Thorax       Date:  1993-06       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.